论文部分内容阅读
目的:探讨乳腺癌组织中ER、PR、C-erbB-2、CD44V6和Ki67的表达与年龄、肿瘤大小、临床分期、淋巴结转移的关系以及它们相互之间的线性关系,同时分析其在乳腺癌的发生、发展中所表现出的临床作用和意义。方法:采用免疫组化S-P法检测103例乳腺癌标本中ER、PR、C-erbB-2、CD44V6和Ki67的表达,并与临床病理因素进行相关性分析。结果:103例患者中ER阳性的有57例(55.34%),PR阳性的有49例(47.57%),C-erbB-2阳性的有39例(37.86%),CD44V6阳性的有68例(66.02%),Ki67阳性的有例(90.29%),其中以Ki67的表达率最高,C-erbB-2的表达率最低;不同年龄、淋巴结是否转移对ER、PR、C-erbB-2、CD44V6和Ki67表达量的差异,无统计学意义(P>0.05);PR的表达与乳腺癌临床分期相关(P<0.05),临床分期越高,PR的表达量越低;C-erbB-2的表达与肿瘤大小相关(P<0.05),肿瘤组织越小,C-erbB-2的表达量越低;ER的表达量和CD44V6的表达量的差异,有统计学意义(P<0.05)。结论:在乳腺癌发病率越来越高的中国以至世界,免疫组化检测ER、PR、C-erbB-2、CD44V6和Ki67的阴阳性表达,可以作为乳腺癌发生、发展的评价指标,联合检测更加有助于早期乳腺癌患者的临床治疗和预后判断,减轻乳腺癌患者的身体和心理的痛苦,为临床医生选择和评估乳腺癌患者的治疗方案提供一些参考,更为下一步的个体化治疗和基因治疗做了一些前序工作。
OBJECTIVE: To investigate the relationship between the expression of ER, PR, C-erbB-2, CD44V6 and Ki67 in breast cancer and their age, tumor size, clinical stage, lymph node metastasis and their linear relationship with each other, The occurrence and development of the clinical role and significance. Methods: The expressions of ER, PR, C-erbB-2, CD44V6 and Ki67 in 103 cases of breast cancer specimens were detected by immunohistochemical S-P method. The correlations were analyzed with clinicopathological factors. Results: Of the 103 patients, 57 were positive for ER (55.34%), 49 (47.57%) were positive for PR, 39 (37.86%) were positive for C-erbB-2 and 68 were positive for CD44V6 66.02%), Ki67 positive cases (90.29%), of which the highest expression rate of Ki67, C-erbB-2 expression rate of the lowest; different ages and lymph nodes metastasis of ER, PR, C-erbB-2, CD44V6 (P <0.05). The expression of PR was correlated with the clinical stage of breast cancer (P <0.05). The higher the clinical stage was, the lower the expression of PR was. The expression of C-erbB-2 (P <0.05). The smaller the tumor tissue was, the lower the expression of C-erbB-2 was. The difference between ER expression and CD44V6 expression was statistically significant (P <0.05). Conclusion: The positive rate of breast cancer in China and the world, immunohistochemical detection of ER, PR, C-erbB-2, CD44V6 and Ki67 positive and negative expression, can be used as a marker of breast cancer development, the development of joint Detection is more helpful to the clinical treatment and prognosis of patients with early breast cancer, alleviating the physical and psychological pain of patients with breast cancer, providing some references for clinicians to select and evaluate the treatment plan for breast cancer patients, and further individuation Some pre-treatment work has been done for treatment and gene therapy.